Publications by authors named "M S Shaefer"
Article Synopsis
- Preventing HIV transmission is essential to ending the HIV epidemic, and effective PrEP has been available since 2012, aiming to help those at highest risk.
- A study compared the demographics of nearly 15,000 PrEP users with over 3,500 newly diagnosed HIV cases to evaluate who was receiving PrEP and identify gaps in access to care.
- The findings revealed disparities in PrEP prescriptions, with older, non-Black males more likely to receive it, and emphasized the need for targeted programs to reach underrepresented populations, particularly young people, women, Black individuals, and intravenous drug users.
Background: Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed upon the individual's experience of treatment and impact on quality of life. The first long-acting injectable antiretroviral therapy for HIV-1 (long-acting cabotegravir + rilpivirine [CAB + RPV LA]) may address challenges associated with oral treatment for HIV-1, such as stigma, pill burden/fatigue, drug-food interactions, and adherence.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the risks of adverse health diagnoses and lab issues linked to daily doses of lamivudine (3TC) in people living with HIV who have moderate kidney function (eGFR between 30 and 49 ml/min).
- It involved analyzing health records from 539 participants, comparing those starting on a 150 mg dose versus a 300 mg dose of 3TC.
- Findings indicated that while there were no major differences in severe lab abnormalities or diagnoses between the two doses, those on 150 mg had higher HIV levels and more health issues, suggesting that 300 mg may not require adjustment for this group unless gastrointestinal or moderate lab problems arise.
Background: Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing, and supportive modelling, underpin further evaluation of every 8 weeks dosing in this trial, which has the potential to offer greater convenience. Our objective was to compare the week 48 antiviral efficacy of cabotegravir plus rilpivirine long-acting dosed every 8 weeks with that of every 4 weeks dosing.
View Article and Find Full Text PDFThe phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled analyses, LA-treated patients (n = 591) demonstrated greater mean improvements from baseline than the CAR group (n = 591) in treatment satisfaction (Week 44, + 3.
View Article and Find Full Text PDF